This approach is currently under early investigation, as Phase I trials are now evaluating crizotinib and the PD-1 inhibitor pembrolizumab in ALK, ROS1, and MET-driven NSCLC [30, 31]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.